Importance Hemoglobin disorders are a considerable public health issue with more than 500 000 affected infants born annually worldwide. First introduced in the 1970s, newborn screening (NBS) for sickle cell disease (SCD) was included in the Recommended Uniform Screening Panel (RUSP) in…
This JAMA Insights discusses the need to fully assimilate evidence from observed and projected effects of climate change on health and invest in developing and implementing effective health protection from preventable climate-sensitive conditions.
This Guide to Statistics and Methods describes design, interpretation, and examples of a stepped-wedge cluster randomized trial.
This case report describes cerebral white matter abnormalities from encephalitis caused by Angiostrongylus cantonensis in a 60-year-old woman.
Importance Prostate cancer is the most common nonskin cancer in men in the US, with an estimated 299 010 new cases and 35 250 deaths in 2024. Prostate cancer is the second most common cancer in men worldwide, with 1 466 680 new cases and…
This JAMA Insights investigates the adverse effects of food insecurity on health and how federal nutrition programs can help mitigate these effects, improving health outcomes and reducing health care utilization.
Importance An estimated 12.8% of US households experienced food insecurity in 2022. Objective To review the evidence on benefits and harms of screening and interventions for food insecurity in health care settings. Data Sources MEDLINE, CINAHL, and the Cochrane Central Registry of Controlled…
Importance According to survey data, 12.8% of households experienced food insecurity in 2022, with 7.7% of households experiencing low food security and 5.1% experiencing very low food security. Nearly one-third of households with incomes below the federal poverty threshold are food…
This Surgical Innovation explores the potential that wearable augmented reality devices have for improving intraoperative imaging, patient outcomes, and surgical workflows.
This JAMA Insights discusses the US Food and Drug Administration approval of Kebilidi, eladocagene exuparvovec, for the treatment of aromatic L-amino acid decarboxylase deficiency in adult and pediatric patients.
© 2025
American Board of Medical Specialties | Policies | Sitemap | Terms of Use | www.abms.org
